Brain Iron Accumulation Linked to Alzheimer's Cognitive Decline
By MedImaging International staff writers Posted on 14 Jul 2020 |
Image: R2* maps of healthy control participants and participants with AD (Photo courtesy of RSNA)
A new magnetic resonance imaging (MRI) study shows iron accumulation in the brain is associated with cognitive deterioration in people with Alzheimer's disease (AD).
Researchers at the Medical University of Graz (Austria) and Ludwig-Maximilians-Universität (LMU; Munich, Germany), conducted a 3T MRI study of brain iron levels using R2* relaxation rate mapping in 100 AD patients (mean age 73 years, 58 women), and 100 matched healthy controls. At 17 month follow up, 56 AD patient underwent neuropsychological testing and brain MRI. All participants had median R2* values calculated in the neocortex and cortical lobes, basal ganglia (BG), hippocampi, and thalami, as a measure of iron deposition.
The results showed median R2* levels were higher in the AD group than in the control group in the BG and total neocortex, and regionally in the occipital and temporal lobes. In addition, R2* values in the temporal lobe reflected changes in iron levels over time and were associated with cognitive decline in individuals with AD, as measured by Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) total score, independent of longitudinal changes in brain volume. The study was published on June 30, 2020, in Radiology.
“These results are all in keeping with the view that high concentrations of iron significantly promote amyloid beta deposition and neurotoxicity in Alzheimer's disease,” said senior author professor of neurology Reinhold Schmidt, MD, of the Medical University of Graz. “Our study provides support for the hypothesis of impaired iron homeostasis in AD and indicates that the use of iron chelators in clinical trials might be a promising treatment target.”
Magnetite (Fe3O4) particles in the human brain were first reported in 1992 in the post‐mortem brain, drawing interest due to its strong interaction with elements in the brain, due to a combination of redox activity, strong magnetic behavior, particle surface charge, and Fenton‐like chemistry. While magnetite appears to serve a physiological purpose in the normal brain, it has been established that it is strongly associated with degenerative diseases of the brain, especially in AD, where magnetite nanoparticles were found associated with tangles and plaques.
Related Links:
Medical University of Graz
Ludwig-Maximilians-Universität
Researchers at the Medical University of Graz (Austria) and Ludwig-Maximilians-Universität (LMU; Munich, Germany), conducted a 3T MRI study of brain iron levels using R2* relaxation rate mapping in 100 AD patients (mean age 73 years, 58 women), and 100 matched healthy controls. At 17 month follow up, 56 AD patient underwent neuropsychological testing and brain MRI. All participants had median R2* values calculated in the neocortex and cortical lobes, basal ganglia (BG), hippocampi, and thalami, as a measure of iron deposition.
The results showed median R2* levels were higher in the AD group than in the control group in the BG and total neocortex, and regionally in the occipital and temporal lobes. In addition, R2* values in the temporal lobe reflected changes in iron levels over time and were associated with cognitive decline in individuals with AD, as measured by Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) total score, independent of longitudinal changes in brain volume. The study was published on June 30, 2020, in Radiology.
“These results are all in keeping with the view that high concentrations of iron significantly promote amyloid beta deposition and neurotoxicity in Alzheimer's disease,” said senior author professor of neurology Reinhold Schmidt, MD, of the Medical University of Graz. “Our study provides support for the hypothesis of impaired iron homeostasis in AD and indicates that the use of iron chelators in clinical trials might be a promising treatment target.”
Magnetite (Fe3O4) particles in the human brain were first reported in 1992 in the post‐mortem brain, drawing interest due to its strong interaction with elements in the brain, due to a combination of redox activity, strong magnetic behavior, particle surface charge, and Fenton‐like chemistry. While magnetite appears to serve a physiological purpose in the normal brain, it has been established that it is strongly associated with degenerative diseases of the brain, especially in AD, where magnetite nanoparticles were found associated with tangles and plaques.
Related Links:
Medical University of Graz
Ludwig-Maximilians-Universität
Remote Controlled Digital Radiography and Fluoroscopy System
Eco Track-DRF - MARS 50/MARS50+/MARS 65/MARS 80
Latest MRI News
- World's First Sensor Detects Errors in MRI Scans Using Laser Light and Gas
- Diamond Dust Could Offer New Contrast Agent Option for Future MRI Scans
- Combining MRI with PSA Testing Improves Clinical Outcomes for Prostate Cancer Patients
- PET/MRI Improves Diagnostic Accuracy for Prostate Cancer Patients
- Next Generation MR-Guided Focused Ultrasound Ushers In Future of Incisionless Neurosurgery
- Two-Part MRI Scan Detects Prostate Cancer More Quickly without Compromising Diagnostic Quality
- World’s Most Powerful MRI Machine Images Living Brain with Unrivaled Clarity
- New Whole-Body Imaging Technology Makes It Possible to View Inflammation on MRI Scan
- Combining Prostate MRI with Blood Test Can Avoid Unnecessary Prostate Biopsies
- New Treatment Combines MRI and Ultrasound to Control Prostate Cancer without Serious Side Effects
- MRI Improves Diagnosis and Treatment of Prostate Cancer
- Combined PET-MRI Scan Improves Treatment for Early Breast Cancer Patients
- 4D MRI Could Improve Clinical Assessment of Heart Blood Flow Abnormalities
- MRI-Guided Focused Ultrasound Therapy Shows Promise in Treating Prostate Cancer
- AI-Based MRI Tool Outperforms Current Brain Tumor Diagnosis Methods
- DW-MRI Lights up Small Ovarian Lesions like Light Bulbs